证券日报网讯圣元环保（300867）7月30日在互动平台回答投资者提问时表示，公司开发的元气小树产 品主要系特膳食品类，注重产品功效，公司也会持续优化完善牛磺酸产品营销推广策略，并根据市场反 馈情况不断提升产品品质、丰富产品种类和优化产品容量、包装等方面设计。 ...

Core Viewpoint - Yong'an Pharmaceutical (002365) has experienced significant stock price fluctuations, with a cumulative deviation exceeding 20% over two trading days, despite the company indicating no major changes in its fundamentals and warning of high speculation risks [1][2]. Financial Performance - Yong'an Pharmaceutical has faced declining revenues for three consecutive years, with reported revenues of 1.462 billion yuan, 973 million yuan, and 839 million yuan for 2022, 2023, and 2024 respectively, reflecting year-on-year declines of 6.58%, 33.48%, and 13.78% [2]. - The core business of taurine generated 635 million yuan in revenue for 2024, accounting for 75.67% of total revenue, but saw a year-on-year decline of 4.14% despite a 16.32% increase in sales volume due to falling prices [2]. - The company incurred a total loss of 17.588 million yuan from the shutdown of its ethylene oxide facility and Qi'an Hydrogen Energy, which accounted for 28.47% of net profit attributable to shareholders [2]. Management and Governance - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, has been placed under investigation and detention, raising concerns about management stability [3]. - Despite the investigation, the company asserts that other board members and senior management are performing their duties normally, and that there has been no change in control or significant impact on daily operations [3]. Future Outlook - Yong'an Pharmaceutical faces multiple challenges, including ongoing performance pressures, obstacles in core business operations, setbacks in new business development, and management changes, raising questions about its future strategies [4].

Core Viewpoint - The company, Yong'an Pharmaceutical, is currently facing a significant event as its actual controller and chairman, Chen Yong, has been placed under investigation and detention by the local authorities, which may impact the company's governance and operations [1][5]. Group 1: Company Background and Structure - Yong'an Pharmaceutical was established in 2001 and went public in March 2010. The company primarily engages in three business segments: research, production, and sales of taurine products; health food; and special dietary foods (creatine) [5]. - The company has a well-established governance structure and internal control mechanisms, ensuring compliance with relevant laws and regulations [5]. Group 2: Recent Financial Performance - In the first quarter of the year, the company reported revenue of 171 million yuan, a year-on-year decrease of 12.96%. The net loss attributable to the parent company was 4.37 million yuan, a decline of 115.23% compared to the previous year [5]. Group 3: Stock Market Activity - Prior to the May Day holiday, Yong'an Pharmaceutical's stock experienced significant volatility, achieving five consecutive daily price increases from April 21 to April 29, with a total increase of nearly 60% during this period [4][5]. - On April 30, the stock closed at a limit down price of 12.91 yuan per share, with a market capitalization of 3.8 billion yuan [6].

Core Viewpoint - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, has been placed under investigation and detention by the Hefe County Supervisory Committee, as announced by the company on May 5 [2]. Company Overview - Yong'an Pharmaceutical was founded in 2001 and went public in March 2010. The company primarily engages in three business areas: research, production, and sales of taurine products; research, production, and sales of health foods; and research, production, and sales of special dietary foods (creatine) [6]. Recent Developments - The company has stated that it is unaware of the progress and conclusions regarding the investigation of Chen Yong and will continue to monitor the situation while adhering to relevant disclosure obligations [4][6]. - Despite the investigation, the company claims that its governance structure and internal control mechanisms are sound, and that other board members and senior management are performing their duties normally. The company's control has not changed, and its production and operational activities remain unaffected [6]. Financial Performance - In the first quarter of this year, the company reported revenue of 171 million yuan, a year-on-year decrease of 12.96%. The net loss attributable to the parent company was 4.3672 million yuan, a year-on-year increase of 115.23% [7]. Stock Market Activity - Prior to the May Day holiday, Yong'an Pharmaceutical's stock experienced significant volatility, recording five consecutive trading days of price increases from April 21 to April 29, with a total increase of nearly 60%. However, the stock closed at a limit down on April 30, at 12.91 yuan per share, with a market capitalization of 3.8 billion yuan [8].